Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)

NCT02667327 is registered in ClinicalTrials.gov with Xequel Bio, Inc. as lead sponsor.

NCT NCT02667327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02667327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)
Lead sponsor
Xequel Bio, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
November 21, 2018
Completion date
May 27, 2020
Enrollment
124 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcers